Embecta Corp. is facing a securities class action lawsuit on behalf of investors who purchased common stock between November 25, 2025 and May 4, 2026. The complaint alleges the company made misleading assurances about the stability and resilience of its pen needle business, which historically comprised over 70% of total revenues, while concealing known weaknesses that would disrupt its financial guidance and second-quarter results. On May 5, 2026, Embecta reported adjusted earnings per share of $0.27 for the second quarter, a roughly 61% decline sequentially and year-over-year, slashed its full-year adjusted EPS guidance to a range of $1.55 to $1.75, and cut its dividend by 93% to $0.01. The stock price tumbled following the announcement, and shareholder rights firm Hagens Berman has opened an investigation into potential securities law violations, with a lead plaintiff deadline of August 17, 2026.
Embecta CorpSecurities class action lawsuit and investigation over alleged concealed revenue risks, plus weak earnings and dividend cut.